Cationic
lipids play a pivotal role in developing novel drug delivery systems for diverse biomedical applications, owing to the success of
mRNA vaccines against
COVID-19 and the Phase III
antitumor agent EndoTAG-1. However, the therapeutic potential of these positively charged
liposomes is limited by dose-dependent toxicity. While an increased content of cationic
lipids in the formulation can enhance the uptake and cytotoxicity toward
tumor-associated cells, it is crucial to balance these advantages with the associated toxic side effects. In this work, we synthesized the cationic
lipid HC-Y-2 and incorporated it into
sialic acid (SA)-modified cationic
liposomes loaded with
paclitaxel to target
tumor-associated immune cells efficiently. The SA-modified cationic
liposomes exhibited enhanced binding affinity toward both RAW264.7 cells and 4T1
tumor cells in vitro due to the increased ratios of cationic HC-Y-2 content while effectively inhibiting 4T1 cell lung
metastasis in vivo. By leveraging electrostatic forces and
ligand-receptor interactions, the SA-modified cationic
liposomes specifically target malignant
tumor-associated immune cells such as tumor-associated macrophages (TAMs), reduce the proportion of cationic
lipids in the formulation, and achieve dual objectives: high cellular uptake and potent antitumor efficacy. These findings highlight the potential advantages of this innovative approach utilizing cationic
liposomes.